-
Mashup Score: 10
Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver fibrosis, researchers reported. In findings from part one of the ESSENCE phase 3 trial published in The New England Journal of Medicine, semaglutide 2.4 mg (Wegovy, Novo Nordisk) conferred greater
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 10
Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver fibrosis, researchers reported. In findings from part one of the ESSENCE phase 3 trial published in The New England Journal of Medicine, semaglutide 2.4 mg (Wegovy, Novo Nordisk) conferred greater
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚨New data from the ESSENCE trial published in @NEJM show #semaglutide can significantly improve steatohepatitis and moderate to severe liver fibrosis for adults with #MASH. @ArunJSanyalVCU discusses how the #GLP1 could change practice @HealioGastro https://t.co/vlXXJUot05
-
🚨New data from the ESSENCE trial published in @NEJM show #semaglutide can significantly improve steatohepatitis and moderate to severe liver fibrosis for adults with #MASH. @ArunJSanyalVCU discusses how the #GLP1 could change practice @HealioGastro https://t.co/vlXXJUot05